AU 105

Drug Profile

AU 105

Alternative Names: AU105

Latest Information Update: 12 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aurora BioPharma
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • Discontinued Sarcoma

Most Recent Events

  • 12 Jul 2016 Discontinued - Phase-I/II for Sarcoma in USA (IV)
  • 05 Jul 2016 Aurora BioPharma completes a phase Ib/IIa trial in Glioblastoma (Newly diagnosed) in USA (Aurora BioPharma pipeline) before July 2016
  • 06 Jun 2016 Aurora BioPharma plans a phase IIb/III trial for Glioblastoma (Newly diagnosed) (Aurora BioPharma Presentation, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top